PHAR
Pharming Group N.V. ADS, each representing 10 ordinary shares
Pharmaceutical Preparations
Best Pharmaceutical Stocks 2026 →
PHAR Stock Analysis: Buy, Sell, or Hold?
$13.40
+0.18 (+1.36%)
▲
5d:
+7.54%
30d:
+41.95%
90d:
+8.5%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (24%)
Quality Score
21/100
Position
EXTENDED
30-Day Fair Range
$9.59 – $12.51
Position: EXTENDED
Forward P/E & Valuation
74.4x
CHEAP
vs 167.6x historical avg
Wall Street Target
$35.10
+161.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$11.75 / $13.48
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: PHAR shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $13.40, which is considered extended relative to its 30-day fair value range of $9.59 to $12.51. From a valuation perspective, the stock is trading at a discount (Forward PE: 74.4) compared to its historical average (167.6). Remarkably, the market is currently pricing in an annual earnings decline of 23.7% over the next few years. This pessimistic expectation contrasts with the company's recent 74.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PHAR is in a downtrend. The price is approaching resistance at $13.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PHAR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $35.10 (+161.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PHAR is in a downtrend. The price is approaching resistance at $13.48. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PHAR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $35.10 (+161.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.59 -
$12.51
Company Quality Score
21/100
(STRONG SELL)
Volume Confirmation
HIGH
Confidence Score
23.8%
Trading Range & Key Levels
30-Day Trading Range
$9.59 -
$12.51
Current vs Trading Range
EXTENDED
Support Level
$11.75
Resistance Level
$13.48
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BEARISH: Price extended above range (+7.1% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 161.9% below Wall St target ($35.10)
- WARNING: Composite score 21/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
74.44
Wall Street Target
$35.10
(+161.9%)
Revenue Growth (YoY)
20.8%
Earnings Growth (YoY)
74.9%
Profit Margin
6.2%
Valuation Discount vs History
-23.7% cheaper
PE vs Historical
74.4 vs 167.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-23.7%
(market-implied from PE analysis)
1-Year Target
$12.06
(-10%)
2-Year Target
$10.85
(-19%)
3-Year Target
$9.77
(-27%)
3-Yr Target (if PE normalizes)
(PE: 74→168)
$21.99
(+64%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 74.4, Growth: -30.8%)
$9.77
(+-27%)
Base:
(SPY PE: 19.9, Growth: -30.8%)
$2.61
(-81%)
Bear:
(PE: 16.9, Growth: -30.8%)
$2.22
(-84%)
📈
Valuation based on Current Earnings
Trailing PE: 41.31 | Current EPS (TTM): $0.32
Bull Case
$8.18
(-39%)
Analyst growth -43.8%, PE expands to 45.4
Base Case
$7.44
(-45%)
Market implied -43.8%, PE stable at 41.3
Bear Case
$8.99
(-33%)
Severe decline -20.0%, PE contracts to 35.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 74.4 to 167.6
Stabilization Target:
$30.17
(+125.1%)
PE Expansion Potential:
+125.1%
Share PHAR Analysis
Share this live PHAR analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (PHAR)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 27, 2026
Daily AI digest
AI Retail Discussion Summary:
Pharming Group reported strong Q3 2026 financial results, exceeding revenue expectations and announcing positive Phase II data for leniolisib in various indications, leading to bullish sentiment on $PHAR.
Key Retail Themes:
Strong Q3 revenue growth
Positive Phase II data for leniolisib
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 4:29 AM ET
Data refreshes hourly during market hours. Next update: 5:29 AM
Data refreshes hourly during market hours. Next update: 5:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 31 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 35 SELL |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$114 | 62 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 41 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive PHAR Research Pages